WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 15, Issue 2, 247-260. Review Article ISSN 2277–7105

AMOXICILLIN DRUG: THE ROLE OF AMOXICILLIN IN MANAGING URINARY TRACT INFECTIONS

Mr. N. Prakash[*1], Mr. E. Thirukumaran[1], Mr. T. Murugan[1], Mr. G. Sagunthan[1], Mr. M. Praveen Kumar[2], Mr. C. Jothimanivannan[3]

[*1]Students, SS Institute of Pharmacy, Sankari, Salem-637301.

[2]Assistant Professor, Department of Pharmacology, SS Institute of Pharmacy, Sankari, Salem 637301.

[3]Professor & Principal, SS Institute of Pharmacy, Sankari, Salem-637301.

Article Received on 15 Dec. 2025,
Article Revised on 05 January 2026,
Article Published on 16 January 2026,
https://doi.org/10.5281/zenodo.18256525

***Corresponding Author**
Mr. N. Prakash
Students, SS Institute of Pharmacy,
Sankari, Salem-637301.

How to cite this Article: Mr. N. Prakash[*1], Mr. E. Thirukumaran[1], Mr. T. Murugan[1], Mr. G. Sagunthan[1], Mr. M. Praveen Kumar[2], Mr. C. Jothimanivannan[3]. (2026) Amoxicillin Drug: The Role of Amoxicillin In Managing Urinary Tract Infections. "World Journal of Pharmaceutical Research, 15(2), 247–260.

ABSTRACT

Community-acquired urinary tract infections are among the most common bacterial infections in women. Therapy for these infections is usually begun before results of microbiological tests are known. Furthermore, in women with acute uncomplicated cystitis, empirical therapy without a pretherapy urine culture is often used. The rationale for this approach is based on the highly predictable spectrum of etiologic agents causing UTI and their antimicrobial resistance patterns. However, antimicrobial resistance among uropathogens causing community-acquired UTIs, both cystitis and pyelonephritis, is increasing. Most important has been the increasing resistance to trimethoprim– sulfamethoxazole TMP–SMX, the current drug of choice for treatment of acute uncomplicated cystitis in women. What are the implications of these trends for treatment of community-acquired UTIs? Preliminary data indicate that clinical cure rates may be lower among women with uncomplicated cystitis treated with TMP–SMX when the infecting pathogen is resistant to TMP–SMX. Women with pyelonephritis also have less bacterial eradication and lower clinical cure rates when treated with TMP–SMX for an infection that is resistant to the drug. Thus, in the outpatient setting, identification of risk factors for TMP–SMX resistance and knowledge of the prevalence of TMP–SMX resistance in the local community become important steps in identifying an

appropriate therapeutic agent. Physicians should consider such factors as in vitro susceptibility, adverse effects, cost-effectiveness, and selection of resistant strains when choosing a treatment regimen. The use of this type of management strategy will be critical to maintaining the safety and efficacy of treatment for acute UTI.

KEYWORDS: Pyelonephritis, uropathogens, Drug resistance, Clinical cure rate, Bacterial eradication, Risk factors for resistance, acute uncomplicated cystitis, Local resistance patterns, In vitro susceptibility, Empirical therapy.

INTRODUCTION

Urinary tract infections (UTIs) are the most frequent bacterial infections in the older patient community, and Escherichia coli is the most common uropathogen in community-dwelling individuals aged >65 years.1 UTI can vary from a mild, uncomplicated, and relatively non-toxic condition to a life-threatening condition, sepsis, which has a mortality rate of 20-40% for the patient. The prevalence of sepsis and its resulting mortality rate is significantly higher and, in fact, disproportionately higher in the increasing ages of the patient, and UTI in men is generally considered to be of a higher degree.234 Additionally, both men and women can be invaded by UTI in the elder years, but the ratio is 2:1 for female preponderance in patients >70 years, as compared to the susceptibility of the female gender in younger patients, which is a staggering 50:1 ratio.5 UTI in patients in the elder years can be difficult to diagnose, as patients in this community are less inclined to demonstrate the common clinical and localized symptoms of urinary infections in the younger patient.6 Furthermore, the rapidly increasing rate of asymptomatic bacteriuria in the elder patients (affecting >20% of women ≥65 years, in contrast to <5% of younger patients) is adding to the diagnostic difficulty and consequently the probable over-diagnosis of UTI in the patients.678.

UTI is the second most common diagnosis for which empirical antibiotics are prescribed in both primary and secondary care, with over 50% of the antibiotics prescribed for a suspected UTI in older people considered to be unnecessarily prescribed. 91011 As the rise in antibiotic

resistance becomes an increasing threat to public health, with approximately 30% of urinary isolates E coli becoming resistant to trimethoprim, national guidelines and antimicrobial stewardship programs have been mooted to address these challenges.1213141516 NHS England, for instance, published the Quality Premium to encourage Clinical Commissioning Groups to decrease antibiotic prescribing in primary care.17 As a consequence of these emerging strategies, a significant reduction in antibiotic prescribing has been documented for the first time in England over the whole healthcare system from 2013 to 2017.161819 A recent publication also demonstrated that prescribing for broader spectrum antibiotics for the management of UTI in older people in primary care has reduced from 2004 to 2014.20 However, the rise in the number of Gram negative bloodstream infections in the meantime has been reported; in response to this, the UK government plans to reduce healthcare-associated Gram negative bloodstream infections in England by 50% by March 2021.16

With an evolving trend of antibiotic use in the face of antimicrobial resistance, now is an even more critical moment to study both the management and outcome of UTIs. Clostridium difficile infections in the elderly are also among those pushing for an evaluation of unnecessary use in this age group. Reduced use of antibiotics may be harmful to the older populations in any case, already at increased risk for complications from UTIs and bloodstream infections. There is also a need for more research on initial treatment strategies for UTIs in primary care; namely, an evaluation of prescribing strategies for no antibiotics at all, defer antibiotics, or use antibiotics immediately and its clinical outcome. We established a direct link between data in English primary care and hospitalization and mortality data at an individual patient level to provide a pragmatic method for evaluation in community care for a large number of older patients with confirmed and probable UTI.

CHEMICAL STRUCTURE OF AMOXICILLIN



MECHANISM OF ACTION

Targeting Cell Wall Synthesis

- The antibiotic amoxicillin consists of a beta-lactam structure, and thus the class of amoxicillin is beta-lactam antibiotics.

Binding to PBPs

- It penetrates the cell wall of bacteria and binds to particular enzymes known as Penicillin-Binding Proteins (PBP)s, or DD-transpeptidases.

Inhibition of Cross-linking

- The cross-linking process is very essential in linking the peptidoglycell polymers, which are found in the rigid layer known as the cell wall. By binding to these proteins, amoxicillin inhibits this step.

Cell lysis and Death

- The inhibition of peptidoglycan synthesis leads to a weakened and injured bacterial cell wall. Water rushes into the cell because of its high osmotic pressure. The cell swells and bursts (lysis), killing the bacterial cell.

Role in Managing UTIs

Bactericidal Effect

- This mode of action is bactericidal, that is to say it is capable of killing the bacteria.

Targeted Pathogens

- It is active against susceptible bacterial strains that may cause urinary tract infections, such as certain species of Escherichia coli and Enterococcus that do not produce beta-lactamase.

Elimination Process

- A large proportion of amoxicillin is excreted unchanged in the urine (about 60%), leading to its peak concentration in the urinary passages, making it useful in localized infections.

Resistance

- Some bacteria have resistance genes which produce enzymes called beta-lactamases, which break down the beta-lactam structure, making these bacteria insensitive to amoxicillin. To counter such resistance, it is used in combination or mixed with

clavulanic acid, which inhibits beta-lactamase enzymes and hence is used under brand names such as Augmentin

TREATMENT OF UTI

- Amoxicillin is not generally considered first-line therapy, but rather a second-line or alternative agent for UTIs. Its use is largely limited by high rates of bacterial resistance, especially from the most common uropathogen, Escherichia coli (E. coli).

Amoxicillin Role

- Amoxicillin kills bacteria by preventing the synthesis of the bacterial cell wall. Its role in UTI management is defined by the following factors:

Second-line Treatment

- Resistance is so common that national and international guidelines often recommend other antibiotics, such as nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), or fosfomycin, as first-line treatments for uncomplicated UTIs.

Susceptibility is Key

- Amoxicillin use should be focused on when the urine culture has confirmed the particular bacteria causing the infection is susceptible to the drug and also does not produce beta-lactamase enzymes, which would inactivate the drug.

Special Populations

- Amoxicillin is considered non-teratogenic and is often a standard option for pregnant women with UTIs that necessitate treatment, given data generally supporting compatibility with pregnancy. It is also used in children, though it requires weight- based dosing.

Complicated UTIs/Recurrence

- Complicated UTIs or recurrence cannot be treated with amoxicillin alone. A combination with clavulanic acid, amoxicillin-clavulanate (e.g., Augmentin), is usually an alternative to manage resistance in a variety of strains.

Limitations

High resistance rates

- In many areas, a considerable proportion of E. coli strains exhibit resistance to

amoxicillin, sometimes with resistance rates as high as 70-80%. Therefore, it should not be used empirically due to its high risk of treatment failure or persistence and recurrence of symptoms.

- In fact, lesser efficacy for uncomplicated cystitis has been documented with amoxicillin-clavulanate compared with agents such as ciprofloxacin, due to the relatively lower clinical and microbiological cure rates associated with poorer eradication of vaginal E. coli by the drug, allowing for early reinfection.

SYMPTOMS

An example is amoxicillin, prescribed for the treatment of UTIs. It may cause some general reactions like nausea, vomiting, and diarrhea. In addition, it may cause some serious, but rare reactions, such as anaphylaxis or 'bad diarrhea.'

Common Side Effects of Medication

The common side effects listed above may resolve themselves, especially after completion of therapy. It is always advisable to take Amoxicillin with food to avoid gastrointestinal disturbances.

- Nausea and vomiting

Diarrhea

- Mild diarrhea may occur. If watery diarrhea is present or persists, it is to be brought to the attention of a medical professional.

Skin Rash

- A few days into treatment, a mild, flat, red rash may appear.
- **Headache.**
- **Abnormal taste** (such as a metallic taste)
- **Vaginal yeast infection** or oral thrush

Serious Side Effects (Contact a Doctor Immediately)

Amoxicillin may occasionally lead to severe side effects. It is essential to discontinue the use of this medication and immediately consult a doctor in case of any of the symptoms that follow:

Symptoms of an allergic reaction

- Skin rash, itching, swelling of the face, lips, tongue, or throat, breathing difficulties, or wheezing.

Severe skin reactions

- Painful red or purple skin that blisters and peels, or red skin with fluid-filled bumps (pustules).

Severe diarrhea with blood

- Watery diarrhea with blood, fever, and abdominal pain persisting for up to two months after treatment discontinuation.

Indicators of a liver problem

- Yellowing of the skin or of the white areas of the eyes (jaundice), dark-colored urine or light-colored stools.

Symptoms of kidney issues:

- Cloudy or bloody urination, or reduction in urination.

Other Rare Side Effects

- Unusual bleeding, bruising, severe fatigue, or seizures.



PHARMACOLOGICAL PROPERTIES OF AMOXICILLIN

Amoxicillin

- This is a bactericidal and broad-spectrum antibiotic that acts by blocking the synthesis of the bacterial cell wall. Its use in urinary tract infections is as a second-line agent for sensitive strains of bacteria, particularly due to resistance patterns among E. coli strains.

Pharmacokinetics

Absorption

- It is acid-stable, well-absorbed, with a high oral bioavailability rate (range 70%–95%) following an oral dose, with peak serum concentrations achieved within 1 to 2 hours.

Distribution

- It penetrates easily into all other tissues and bodily fluids, except for the brain and spinal fluid, in which case the meninges can be inflamed. It is plasma protein-bound to a low extent, about 20%.

Elimination

- It excretes most of the drug (about 60%) in urine in unaltered form in 6-8 hours, leading to concentrated levels in urine, which is effective against susceptible microorganisms. The half-life is about 60 minutes.

Spectrum of Activity

- It is active against a broad spectrum of Gram-positive bacteria (such as Streptococci and Enterococci) and several Gram-negative organisms (sensitive strains of Escherichia coli and Proteus mirabilis).

Role in the Management of UTIs

Current Use

- Amoxicillin is not usually a drug of choice for uncomplicated UTIs owing to the high level of resistance to the agent among common uropathogens, including beta- lactamase-producing E. coli. The drug of choice usually involves nitrofurantoin, fosfomycin, or trimeth

Indication

- Indicated in cases where a urine culture has proved the susceptible organism to be amoxicillin-sensitive (beta-lactamase-negative bacteria), and preferably in special cases such as pregnant women for whom the drug has been found to be safe (FDA category B).

Combination Therapy

- To counter the resistance offered by beta-lactamase, amoxicillin is used in combination with beta-lactamase inhibitors, like clavulanic acid, as seen in amoxicillin and clavulanate combination tablets or capsules.

- As combination formulations, these tablets or capsules of amoxicillin and clavulanate have both qualitative and quantitative compendial standards, which include

PHARMACODYNAMIC

Pharmacodynamic (PD) Properties

Mechanism of Action

- Amoxicillin, a beta-lactam class of antibiotics, acts by binding to the penicillin binding proteins (PBPs) of a microbial cell wall, especially PBP-1A. This results in the irreversible binding and a subsequent lack of the last transpeptidase step in the synthesis of peptidoglycan, an important multifaceted compound comprising the cell wall of microbes. As a consequence of the puedergic cell wall, the microbes are lysed and die.
- Time-Dependent Killing: The effectiveness of amoxicillin is, to some extent, based on how long the concentration of the free form is above the MIC of the microbe and not on peak levels reached. In order to get optimal cure rates in infections of the urinary tract, there needs to be a cumulative T> MIC of approximately 30 hours, according to some clinical studies.

Spectrum of Activity: **UTIs**

- The drug is active against susceptible strains of common UTIs, such as bacteria that do not produce beta-lactamase enzymes:
- Enterococcus fa
- Escherichia coli (Certain strains that lack
- Proteus mirabil

Pharmacokinetic (PK) Properties

High Urinary Excretion

- The high urinary excretion of amoxicillin, where between 60% and 85% of the administered dose is excreted unchanged in the urine within a period of 6-8 hours, contributes largely to the effectiveness of amoxicillin in UTI infections. The drug achieves high concentrations in the urine, exceeding MIC levels of many susceptible bacterial pathogens.

Oral Bioavailability

- The bioavailability of amoxicillin is quite high, ranging from 77% to 93%, indicating that

a substantial amount of the orally ingested medication is well absorbed to attack the infection.

Role and Limitations in UTI Management

Because of its

- Not a First-Line Agent (Empirical Therapy): Owing to the high prevalence of beta-lactamase-producing strains of E. coli and other Gram-negative organisms, amoxicillin on its own may not be considered a first-line agent in the treatment of uncomplicated cystitis if considering empirical therapy because the antibiotic may not act against beta-lactamase producers.
- Use in Susceptible Cases: It can be extremely effective in UTIs due to a specific case of a confirmed susceptible isolate, particularly Enterococcus species, that do not tend to produce Beta-lactamase.

Resistant Crosses

- In order to extend the spectrum of activity and overcome Beta-lactamase mediated resistances, amoxicillin is often combined with a Beta-lactamase inhibitor, such as clavulanic acid. The combination product is known as Co-amoxiclav. The action of clavulanic aciddesactivates.

Dosing Implications

- It is usually recommended that to keep the required T > MIC, a dose of amoxicillin (or co-amoxiclav) for the treatment of uncomplicated cystitis may be 500 mg every 8 hours or 875 mg every 12 hours for a period of 5 days.

Merits of Amoxicillin in UTI Management

Effectiveness when susceptible

- When a urine culture specifically documents that the particular bacteria causing the infection, usually certain strains of E. coli, Enterococcus faecalis, or Proteus mirabilis, are susceptible to it, amoxicillin is very effective.

Safety profile

- Amoxicillin is usually well tolerated by most patients, including children and pregnant women, under normal medical supervision.

High urinary concentrations

- The drug is excreted mainly through the kidneys; thus, high concentrations in urine help to combat the infection right at its source.
- The affordability and accessibility of amoxicillin are warranted since it is a widely available generic medication.

Combination therapy

- When combined with clavulanic acid-as in Augmentin-its spectrum of activity expands to include activity against bacteria that produce beta-lactamase enzymes, which would inactivate the pure amoxicillin.

Demerits of Amoxicillin in UTI Management

High bacterial resistance

- Most common UTI-causing bacteria, especially E. coli, are resistant to amoxicillin, which makes this agent unreliable for empirical treatment.

Not a first-line therapy

- Resistance issues have excluded amoxicillin from being recommended as one of the first-line treatment options in major medical guidelines for uncomplicated UTIs.

Poor efficacy relative to alternative therapies

- Amoxicillin-clavulanate demonstrates clinically and microbiologically poorer cure rates than ciprofloxacin or other advocated agents in the treatment of acute uncomplicated cystitis.

Development of antibiotic resistance

- Overuse or abuse-as in not taking the entire dose-of amoxicillin carries the risk of developing bacterial strains resistant to antibiotics, which could mean longer medical treatment and increased healthcare costs in the future.

Common side effects

- Diarrhea, nausea, vomiting, headache, and rash are common side effects. Combination with clavulanic acid is also linked to higher frequencies of GI side effects.

Risk of recurrence

- Several studies have identified higher recurrence rates of UTIs with the use of

amoxicillin when compared to other effective agents.

Hypersensitivity

- It is a penicillin-class antibiotic; hence, it may cause severe allergic reactions such as anaphylaxis and hives among sensitive patients. It is contraindicated in patients who reported a history of penicillin allergy.

CONCLUSION

Urinary tract infections remain a major cause of morbidity across all age groups, particularly among women and the elderly population. The increasing prevalence of antimicrobial resistance among common uropathogens has significantly influenced the choice of antibiotics used in UTI management. Amoxicillin, a widely used beta-lactam antibiotic, plays a limited but important role in the treatment of UTIs when applied judiciously. Although it possesses favorable pharmacokinetic properties such as high oral bioavailability, good tissue penetration, and high urinary excretion, its effectiveness is compromised by widespread resistance, especially among *Escherichia coli* strains, which are the predominant causative organisms of community-acquired UTIs.

As a result, amoxicillin is no longer recommended as a first-line empirical therapy for uncomplicated UTIs. Its use should be guided by urine culture and sensitivity testing to ensure bacterial susceptibility, particularly in infections caused by beta-lactamase-negative organisms such as *Enterococcus faecalis* and selected strains of *E. coli* and *Proteus mirabilis*. The combination of amoxicillin with clavulanic acid has expanded its therapeutic utility by overcoming beta-lactamase-mediated resistance; however, even this combination demonstrates lower clinical and microbiological cure rates compared to recommended first-line agents.

Despite these limitations, amoxicillin maintains clinical relevance due to its safety profile, cost-effectiveness, and suitability for special populations such as pregnant women and pediatric patients. Rational prescribing, adherence to antimicrobial stewardship principles, and awareness of local resistance patterns are essential to optimizing treatment outcomes. Overall, while amoxicillin is not a preferred empirical agent, it remains a valuable option in carefully selected cases of urinary tract infections.

REFERENCES

1. González-Bello, C., Rodríguez, D., Pernas, M., Rodriguez, A., & Colchón, E. (2019). β-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs. Journal of medicinal chemistry, 63(5): 1859-1881.
2. Sun, P., Zhao, T., Xiao, H., Wang, J., Zhang, S., & Cao, X. (2021). The bioavailability and pharmacokinetics of an amoxicillin–clavulanic acid granular combination after intravenous and oral administration in swine. Journal of Veterinary Pharmacology and Therapeutics, 44(1): 126-130.
3. Ahmadi, H., Ebrahimi, A., & Ahmadi, F. (2021). Antibiotic therapy in dentistry. International journal of dentistry, 2021.
4. Pulingam, T., Parumasivam, T., Gazzali, A. M., Sulaiman, A. M., Chee, J. Y., Lakshmanan, M., … & Sudesh, K. (2022). Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. European Journal of Pharmaceutical Sciences, 170: 106103.
5. Vaou, N., Stavropoulou, E., Voidarou, C., Tsigalou, C., & Bezirtzoglou, E. (2021). Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives. Microorganisms, 9(10): 2041.
6. Ryan KJ. Urinary Tract Infections. In: Ryan KJ, Ray CG editors. Sherris Medical Microbiology.. McGraw-Hill: New York; 2003; 867–71.
7. European Center for Disease Prevention and Control. Reporting on 2009 surveillance data and 2010 epidemic intelligence data Annual Epidemiological Report 2011. Stockholm; 2011.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteen Informational Supplement, M100-S18. Wayne; 2008.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteen Informational Supplement, M100-S18. Wayne; 2012.
10. Kizirgil A, Demirdag K, Ozden M, Bulut Y, Yakupogullari Y, Toraman ZA. In vitro activity of three different antimicrobial agents against ESBL producing Escherichia coli and Klebsiella pneumoniae blood isolates. Microbiol Res., 2005; 160(2): 135–40.
11. González-Bello, C., Rodríguez, D., Pernas, M., Rodriguez, A., & Colchón, E. (2019). β-Lactamase inhibitors to restore the efficacy of antibiotics against superbugs. Journal of medicinal chemistry, 63(5): 1859-1881.
12. Sun, P., Zhao, T., Xiao, H., Wang, J., Zhang, S., & Cao, X. (2021). The bioavailability and pharmacokinetics of an amoxicillin–clavulanic acid granular combination after

intravenous and oral administration in swine. Journal of Veterinary Pharmacology and Therapeutics, 44(1): 126-130.

13. Ahmadi, H., Ebrahimi, A., & Ahmadi, F. (2021). Antibiotic therapy in dentistry. International journal of dentistry, 2021.
14. Pulingam, T., Parumasivam, T., Gazzali, A. M., Sulaiman, A. M., Chee, J. Y., Lakshmanan, M., … & Sudesh, K. (2022). Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome. European Journal of Pharmaceutical Sciences, 170: 106103.
15. Vaou, N., Stavropoulou, E., Voidarou, C., Tsigalou, C., & Bezirtzoglou, E. (2021). Towards advances in medicinal plant antimicrobial activity: A review study on challenges and future perspectives. Microorganisms, 9(10): 2041.
16. Lima, L. M., da Silva, B. N. M., Barbosa, G., & Barreiro, E. J. (2020). β-lactam antibiotics: An overview from a medicinal chemistry perspective. European journal of medicinal chemistry, 208: 112829.
17. Shalaby, M. A. W., Dokla, E. M., Serya, R. A., & Abouzid, K. A. (2020). Penicillin binding protein 2a: An overview and a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 199: 112312.
18. Al-Tamimi, M., Abu-Raideh, J., Albalawi, H., Shalabi, M., & Saleh, S. (2019). Effective oral combination treatment for extended-spectrum beta-lactamase-producing Escherichia coli. Microbial Drug Resistance, 25(8): 1132-1141.
19. Arab, O., Al-Kayali, R., Khouri, A., & Kaddour, S. H. (2023). Resistance patterns of bacterial pathogens causing lower respiratory tract infections: Aleppo-Syria. Annals of Medicine and Surgery, 10-1097.
20. Gibson, P. S., & Veening, J. W. (2023). Gaps in the wall: understanding cell wall biology to tackle amoxicillin resistance in Streptococcus pneumoniae. Current Opinion in Microbiology, 72: 102261.